The characterization of pleural metastases from lung adenocarcinoma is often limited to single biologic features.
Methods
The present paper describes the cellular kinetic parameters, as well as immunocytochemical, ultrastructural and genetic characteristics of the new DV90 cell line, established from the pleural effusion of a stage IV lung adenocarcinoma.
Results
The cell line has a diploid DNA content, a doubling time of 24 h and 7% cloning efficiency, it is tumorigenic in nude mice. Ultrastructural investigation revealed the typical features of lung adenocarcinoma; the diagnosis was confirmed by its immunohistochemical reactivity with a panel of monoclonal antibodies specifically capable of identifying adenocarcinoma cells. Genetic analysis revealed a 46 X, –Y, +8, der (6)t(6?)(q27;?) karyotype and hyperexpression of the protein codified by genes Her2/Neu and p53.
Conclusion
The importance of multidisciplinary biologic characterization in identifying the origin and biological behavior of pleural metastases deriving from lung adenocarcinoma is discussed.
BattiforaH., KopinskiM.: Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach.Cancer, 55: 1679–1685, 1985.
2.
BenjaminC.J., RitchieA.C.: Histological staining for the diagnosis of mesothelioma.Am. J. Med. Technol., 48: 905–908, 1982.
3.
BlobelG.A., MollR., FrankeW.W., KayserK.W., GouldV.E.: The intermediate filament cytoskeleton of malignant mesothelioma and its diagnostic significance.Am. J. Pathol., 121: 235–237, 1985.
4.
BolenJ.W., HammarS.P., McNuttM.A.: Reactive and neoplastic serose tissue. A light microscopic, ultrastructural and immunohistochemical study.Am. J. Surg. Pathol., 10: 34–47, 1986.
5.
CagleP.T., TaylorL.D., SchwartzM.R., RamzyI., ElderF.B.: Cytogenetic abnormalities common to adenocarcinoma metastatic to the pleura.Cancer Genet. Cytogenet., 39: 219–225, 1989.
6.
ChurgA.: Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.Am. J. Surg. Pathol., 9: 360–365, 1985.
7.
CibasE.S., CorsonJ.M., PinkusG.S.: The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusion.Human Pathol., 18: 67–74, 1987.
8.
DeitchA.D., LawH., WhiteR.D.: A stable propidium iodide procedure for flow cytometry.J. Histochem. Cytochem., 3B: 913–917, 1979.
9.
JinY., MondhalL.N., HeimS., SchullerH., MitelmanF.: Isochromosome (8q) or i(9q) in three adenocarcinomas of the lung.Cancer Genet. Cytogenet., 33: 11–17, 1988.
10.
KennedyA., BurginP.D.A comparison of different methods of detecting mucin in adenocarcinoma of the lung.Br. J. Dis. Chest., 69: 137–143, 1975.
11.
LeeJ.S., PathakS., HopwoodV., TomasovicB., MullinsT.D., BakerF.L., SpitzerG., NeodhartJ.A.: Involvement of chromosome 7 in primary lung tumor and non malignant normal lung tissue.Cancer Res., 47: 6349–6352, 1987.
12.
MarkR.W., LidyT., MillsS.E., LegierJ.F., ManivelC.: Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma. A histochemical, ultrastructural and immunohistologic study of 103 cases.Human Pathol., 21: 759–766, 1990.
13.
McGregorD.H., DixonA.Y., McGregorD.K.: Adenocarcinoma of the lung: a comparative diagnostic study using light and electron microscopy.Human Pathol., 19: 910–913, 1988.
14.
MitelmanF.: Catalog of Chromosome Aberrations in Cancer, 3rd Edn.R. Liss, New York, 1988.
15.
OrdonezN.G.: The immunohistochemical diagnosis of mesothelioma: differentiation of mesothelioma and lung adenocarcinoma.Am. J. Surg. Pathol., 13: 276–291, 1989.
16.
PerrinL.S., CaporosoN.E., ForresterK., HarrisC.C., TrumpB.F., HooverR.N., WestonA.: Allelic frequency of a P53 polymorphism in lung cancer cases and controls.Proc. Am. Assoc. Cancer Res., 33: a1709, 1992.
17.
PfaltzM., OdermattB., ChristenB., RuttnerJ.R.: Immunohistochemistry in the diagnosis of malignant mesothelioma.Virchows Arch. (A), 411: 387–393, 1987.
18.
PulfordK.A., SiposA., CordellJ.L., StrossW.P., MasonD.Y.: Distribution of the CD68 macrophage/myeloid associated antigen.Int. Immunol., 2: 973–980, 1990.
19.
ReyJ.A., BelloM.J., De CamposJ.M., KusakE., MorenoS., BenitezJ.: Deletion 3p in two adenocarcinomas metastatic to the brain.Cancer Genet. Cytogenet., 25: 355–360, 1987.
20.
SandbergA.A., Turc CarelC., GemmiL.L.R.M.: Chromosomes in solid tumors and beyond.Cancer Res., 48: 1049–1059, 1988.
21.
ScheiderP.M., StoehrN., BoehmJ., ManningJ., FinkU., PraeuerH.W., RothJ.A.: Differential transcriptional and posttranscriptional regulation of NEU gene expression in all major histological types of human cancer.Proc. Annu. Meet. Am. Assoc. Cancer Res., 34: A3178, 1993.
22.
SeabrightM.: A rapid handing technique for human chromosomes.Lancet, 2: 971–973, 1971.
23.
SteibanK., BattiforaH., BurkeJ.S.: Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of LEU Ml antigen.Am. J. Pathol., 123: 212–219, 1986.
24.
SzpakC.A., JohnstonW.W., RoggliV., KolbeckJ., LottichS.C., VollmerR., ThorA., ScholmJ.: The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am.J. Pathol., 122: 252–260, 1986.
25.
TsaiC.M., ChangK.T., PerngR.P.: Mitsudomi I., Chen M.H., Kadoyama c., Gazdar A.F.: Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with Her2/Neu gene expression but not with RAS gene mutation. J. Natl.Cancer Inst.,85, 897–901, 1993.
26.
WagnerJ.C., MundayD.E., HaringtonJ.S.: Histochemical demonstration of hyaluronic acid in pleural mesothelioma.J. Pathol. Bacteriol., 84: 73–78, 1962.
27.
WarholM.J., HickeyW.F., CorsonJ.M.: Malignant mesothelioma ultrastructural distinction from adenocarcinoma.Am. J. Surg. Pathol., 6: 307–314, 1982.
28.
WarholM.J., HickeyW.F., CorsonJ.M.: Malignant mesothelioma: Ultrastructural distinction from adenocarcinomaas of the lung and breast.Human Pathol., 16: 50–55, 1985.
29.
WestraW.H., SlebosR.J., OfferhausG.J., GoodmanS.N., EversS.G., KenslerT.W., AskinF.B., RodenhiusS., HrubanR.H.: K-RAS oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-RAS mutations are an early and irreversible event in the development of adenocarcinoma of the lung.Cancer, 72: 432–438, 1993.
30.
WickM.R.: Monoclonal antibodies to carcinoembryonic antigen in diagnostic immunohistochemistry. In: Monoclonal Antibodies in Diagnostic Immunohistochemistry.WickM.R., SiegelP. (Eds.), R. Liss, NY, pp. 539–567, 1988.
31.
WirthP.R., LegierJ., WrightG.L.: Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.Cancer, 67: 655–665, 1991.
